Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Novo Nordisk’s Wegovy Approved in China; But Patent Expires in Two Years

publication date: Jun 27, 2024

Novo Nordisk was approved to launch Wegovy, one of its two GLP-1 drugs, in China for long-term weight management in obese and overweight people who have at least one weight-related health condition. But Novo Nordisk’s China patent only has two years left to run. However, Novo Nordisk may not launch Wegovy soon, because of the short-term patent and because the company faces worldwide shortages of the very popular weight loss drug. China’s generic drug industry is developing 15 knock-off versions of the drug, with 11 of them in late clinical trials. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here